Загрузка...
Fludarabine, cyclophosphamide, and rituximab (FCR) plus GM-CSF as frontline treatment for patients with Chronic Lymphocytic Leukemia
FCR, the standard of care for frontline treatment of CLL patients, is associated with a high rate of neutropenia and infectious complications. GM-CSF reduces myelosuppression and can potentiate rituximab activity. We conducted a clinical trial combining GM-CSF with FCR for frontline treatment of 60...
Сохранить в:
| Опубликовано в: : | Leuk Lymphoma |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4487862/ https://ncbi.nlm.nih.gov/pubmed/23808813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2013.819574 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|